Is preoperative tumor size a critical prognostic factor for patients with Borrmann type III gastric cancer?
Preoperative tumor size is an IPF for patients with Borrmann type III gastric cancer and CY0. Thus, preoperative tumor size may be a useful factor for deciding on whether neoadjuvant chemotherapy is indicated.
Our findings demonstrated that additional resources, such as care services, should be provided for sufferers of EOD, in order to allow family caregivers to cope with difficulties associated with patient behavioural problems.